Expression of CD44 Isoforms on Isolated Bone Marrow Plasma Cells and Peripheral CD19⁺ B Cells of Patients with Multiple Myeloma and Healthy Individuals

References

• Horst E., Meijer C. J.L.M., Radaszkiewicz T., Ossekoppele G. J., Van Krieken J. H.J.M., Pals S. T. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44), LFA-1 (CD 11dl8), and ICAM-1 (CD54). Leukemia 1990; 4: 595–599
   PubMed Web of Science ®Google Scholar
• Pals S. T., Horst E., Ossekoppele G. J., Figdor C. G., Scheper R. J., Meijer C. J. Expression of lymphocyte homing receptor (CD44) as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989; 73: 995–998
   Google Scholar
• Van Riet I., Heirman C., Lacor P., De Waele M., Thielemans K., Van Camp B. Detection of monoclonal B cells in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. British Journal of Haematology 1989; 73: 289–295
   PubMed Web of Science ®Google Scholar
• Billadeau D., Quam L., Thomas W., Kay N., Greipp P., Kyle R., Oken M. M., van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C., Barille S., Puthier D., Rapp M. J., Harousseau J. L., Bataille R., Amiot M. Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumour spreading, and immortalization. Cancer Research 1995; 55: 3647–3653
   PubMed Web of Science ®Google Scholar
• Günthert U. CD44: A multitude of isoforms with diverse functions. Current Topics in Microbiology and Immunology 1993; 184: 47–63
   PubMedGoogle Scholar
• Lesley J., Hyman R., Kincade P. W. CD44 and its interaction with the extracellular matrix. Advances in Immunology 1993; 54: 271–335
   PubMed Web of Science ®Google Scholar
• Webb D. S.A., Shimizu Y., Van Seventer G. A., Shaw S., Gerard T. L. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990; 249: 1295–1297
   PubMed Web of Science ®Google Scholar
• Thomas L., Byers R., Vink J., Stamenkovic I. CD44H regulates tumour cell migration on hyaluronate-coated substrate. Journal of Cell Biology 1992; 118: 971–977
   PubMed Web of Science ®Google Scholar
• Jalkanen S., Bargatze R E, Herron L. R., Butcher E. C. Homing receptors and the control of lymphocyte migration. Immunological Reviews 1986; 91: 39–60
   PubMed Web of Science ®Google Scholar
• Miyake K., Underhill C. B., Lesley J., Kincade P. W. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. Journal of Experimental Medicine 1990; 172: 69–75
   PubMed Web of Science ®Google Scholar
• Günthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24
   PubMed Web of Science ®Google Scholar
• Heider K. H., Hofmann M., Horst E., Van Den Berg E, Ponta H., Herrlich P., Pals S. T. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. Journal of Cell Biology 1993; 120: 227–233
   PubMed Web of Science ®Google Scholar
• Koopman G., Heider K. H., Horst E., Adolf G. R., Van Den Berg E, Ponta H., Herrlich P., Pals S. T. Activated human cells and aggressive non-Hodgkin's lymphomas express a honiologue of the rat metastasis-associated variant of CD44. Journal of Experimental Medicine 1993; 1778: 897–904
   Web of Science ®Google Scholar
• Stauder R., Eisterer R., Thaler J., Giinthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995; 85: 2885–2899
   PubMed Web of Science ®Google Scholar
• Leo R., Boeker M., Peest D., Hein R., Bartl R., Gessner J. E., Selbach J., Wacker G., Deicher H. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg +is the common phenotype of myeloma cells. Annals of Hematology 1992; 64: 132–139
   PubMed Web of Science ®Google Scholar
• Harada H., Kawano M. M., Huang N., Harada Y., Iwato K., Tanabe O., Tanaka H., Sakai A, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658–2663
   PubMed Web of Science ®Google Scholar
• Joshua D., Wolf M., Matthews J., Tan L., Sheridan W., Pilkington G., Page F. Peripheral blood lymphocyte surface antigen expression and prognosis in myeloma: Australian leukaemia study group study. Leukemia and Lymphoma 1994; 14: 303–309
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Smith A. M., Szczepek A., Mant M. J., Belch A. R., Pilarski L. M. In multiple myeloma, clonotypic B cells are detectable among CD19′ peripheral blood cells expressing CD38, CD56, and monotypic Ig light Chain. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation for incomplete observations. Journal of the American Statistic Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Vidriales M. B., Anderson K. C. Adhesion of multiple myeloma cells to the bone marrow microenvironment: Implications for future therapeutic strategies. Molecular Medicine Today 1996; 2: 425–431
   PubMedGoogle Scholar
• Hawley R. G., Wang M. H., Fong A. Z., Hawley T. S. Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas. Clinical and Experimental Metastasis 1993; 11: 213–226
   PubMed Web of Science ®Google Scholar
• Van Riet I., Camp B. V. The involvement of adhesion molecules in the biology of multiple myeloma. Leukemia and Lymphoma 1993; 9: 441–452
   PubMed Web of Science ®Google Scholar
• Stauder R., Van Driel M., Schwlrzler C., Thaler J., Lokhorst H. M., Kreuser E. D., Bloem A. C., Gunthert U., Eisterer W. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996; 88: 3101–3108
   PubMed Web of Science ®Google Scholar
• Masellis-Smith A., Belch A. R., Maut M. J., Turley E. A., Pilarski L. M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood 1996; 87: 1891–1899
   PubMed Web of Science ®Google Scholar
• Masellis-Smith A, Blech A. R., Mant M. J., Pilarski L. M. Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7. Cancer Research 1997; 57: 930–936
   PubMed Web of Science ®Google Scholar
• Sleeman J., Rudy W., Hofmann H., Holl J., Herrlich P., Ponter H. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. Journal of Cell Biology 1996; 135: 1139–1150
   PubMed Web of Science ®Google Scholar
• Okada H., Yoshida J., Sokabe M., Wakabayashi T., Hagiwara M. Suppression of CD44 expression decreases migration and invasion of human glioma cells. International Journal of Cancer 1996; 66: 255–260
   PubMed Web of Science ®Google Scholar
• Nishina H., Inageda K., Takahashi K., Hoshino S., Ikeda K., Katda T. Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity. Biochemical and Biophysical Research Communications 1994; 203: 1318–1323
   PubMed Web of Science ®Google Scholar